Neuromodulators and therapeutic targets in neuropathic pain: From molecules to man

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 3, 2009, Pages 175-183

  Bermejo, Pedro E ^a   Anciones, B ^a  

^a Hospital de la Zarzuela   (Spain)

Author keywords

Antiepileptic; Gabapentin pregabalin; Neuromodulator; Neuropathic pain; Oxcarbacepine; Topiramate; Zonisamide

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE; ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CANNABINOID RECEPTOR; CARBAMAZEPINE; CYCLIC NUCLEOTIDE GATED CHANNEL; ETIRACETAM; GABAPENTIN; GLUTAMATE RECEPTOR; HARKOSERIDE; LAMOTRIGINE; OPIATE RECEPTOR; OXCARBAZEPINE; POTASSIUM CHANNEL; PREGABALIN; RETIGABINE; SODIUM CHANNEL; SUBSTANCE P; TOPIRAMATE; VANILLOID RECEPTOR; ZONISAMIDE;

ADDICTION; ALCOHOLISM; ANALGESIC ACTIVITY; ANTINOCICEPTION; BIPOLAR DEPRESSION; CANCER PAIN; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CUBITAL TUNNEL SYNDROME; DIABETIC NEUROPATHY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EATING DISORDER; ESSENTIAL TREMOR; FIBROMYALGIA; GABAERGIC SYSTEM; GLOSSODYNIA; GLOSSOPHARYNGEAL NEURALGIA; HUMAN; IMPULSE CONTROL DISORDER; MENTAL DISEASE; MESOLIMBIC DOPAMINERGIC SYSTEM; MIGRAINE; NERVE CELL MEMBRANE STEADY POTENTIAL; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; NOCICEPTIVE RECEPTOR; NONHUMAN; NORADRENERGIC SYSTEM; PAIN THRESHOLD; PERIPHERAL NEUROPATHY; PHANTOM PAIN; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; RADICULAR PAIN; RADICULOPATHY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SYNAPSE VESICLE; SYNAPTIC INHIBITION; TOOTH PAIN; TRIGEMINUS NEURALGIA; VULVODYNIA;

EID: 70349504198     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709788680661     Document Type: Review

References (100)

1. Backonja, M.; Galer, B.S. Pain assessment and evaluation of patients who have neuropathic pain. Neurol. Clin., 1998, 16, 775-90.
2. Rowbotham, M.; Harden, N.; Stacey, B.; Bernstein, P.; Magnus-Miller, L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA, 1998, 280, 1837-42.
3. Backonja, M.; Beydoun, A.; Edwards, K.R.; Schwartz, S.L.; Fonseca, V.; Hes, M.; LaMoreaux, L.; Garofalo, E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA, 1998, 280, 1831-6.
4. Armijo, J.A.; Adín, J.; Sánchez, M.B. Mechanism of action of antiepileptic drugs and new antiepileptic drugs. Rev. Neurol., 2006, 43, S17-41.
5. Cunha, J.M.; Cunha, F.Q.; Poole, S.; Ferreira, S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br. J. Pharmacol., 2000, 130, 1418-24.
6. Waxman, S.G. Acquired channelopathies in nerve injury and MS. Neurology, 2001, 56, 1621-7.
7. Caviedes, B.E.; Herranz, J.L. Advances in physiopathology and the treatment of neuropathic pain. Rev. Neurol., 2002, 35, 1037-48.
8. Gurtu, S.; Smith, P.A. Electrophysiological characteristics of hamster dorsal root ganglion cells and their response to axotomy. J. Neurophysiol., 1988, 59, 408-23.
9. Bolay, H.; Moskowitz, M.A. Mechanisms of pain modulation in chronic syndromes. Neurology, 2002, 59, S2-7.
10. Mannion, J.R.; Woolf, C.J. Pain mechanism and management: a central perspective. Clin. J. Pain, 2000, 16, 144-56.
11. Zhang, X.; Wu, J.; Lei, Y.; Fang, L.; Willis, W.D. Protein phosphatase 2A regulates central sensitization in the spinal cord of rats following intradermal injection of capsaicin. Mol. Pain, 2006, 20, 2-9.
12. Woolf, C.J.; Shortland, P.; Coggeshall, R.E. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature, 1992, 355, 75-8.
13. Abraham, K.E.; McGinty, J.F.; Brewer, K.L. The role of kainic acid/AMPA and metabotropic glutamate receptors in the regulation of opioid mRNA expression and the onset of pain-related behavior following excitotoxic spinal cord injury. Neuroscience, 2001, 104, 863-74.
14. Eide, P.K. Wind-up and the NMDA receptor complex from a clinical perspective. Eur. J. Pain, 2000, 4, 5-15.
15. Lidbeck, J. Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. Pain Res. Manag., 2002, 7, 81-92.
16. Devor, M. Sodium channels and mechanisms of neuropathic pain. J. Pain, 2006, 7, S3-12.
17. Ekberg, J.; Adams, D.J. Neuronal voltage-gated sodium channel subtypes: key roles in inflammatory and neuropathic pain. Int. J. Biochem. Cell Biol., 2006, 38(12), 2005-10.
18. Zhao, P.; Barr, T.P.; Hou, Q.; Dib-Hajj, S.D.; Black, J.A.; Albrecht, P.J.; Eisenberg, E.; Wymer, J.P.; Rice, F.L.; Waxman, S.G. Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: evidence for a role in pain. Pain, 2008, 139, 90-105.
19. Lindia, J.A.; Köhler, M.G.; Martin, W.J.; Abbadie, C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain, 2005, 117, 145-53.
20. Henry, M.A.; Freking, A.R.; Johnson, L.R.; Levinson, S.R. Sodium channel Nav1.6 accumulates at the site of infraorbital nerve injury. BMC Neurosci., 2007, 27, 56.
21. Dib-Hajj, S.D.; Cummins, T.R.; Black, J.A.; Waxman, S.G. From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci., 2007, 30, 555-63.
22. Hoyt, S.B.; London, C.; Ok, H.; González, E.; Duffy, J.L.; Abbadie, C.; Dean, B.; Felix, J.P.; Garcia, M.L.; Jochnowitz, N.; Karanam, B.V.; Li, X.; Lyons, K.A.; McGowan, E.; Macintyre, D.E.; Martin, W.J.; Priest, B.T.; Smith, M.M.; Tschirret-Guth, R.; Warren, V.A.; Williams, B.S.; Kaczorowski, G.J.; Parsons, W.H. Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett., 2007, 17, 6172-7.
23. McGaraughty, S.; Chu, K.L.; Scanio, M.J.; Kort, M.E.; Faltynek, C.R.; Jarvis, M.F. A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J. Pharmacol. Exp. Ther., 2008, 324, 1204-11.
24. Okuse, K.; Malik-Hall, M.; Baker, M.D.; Poon, W.Y.; Kong, H.; Chao, M.V.; Wood, J.M. Annexin II light chain regulates sensory neuron-specific sodium channel expression. Nature, 2002, 417, 653-6.
25. Cummins, T.R.; Rush, A.M. Voltage-gated sodium channel blockers for the treatment of neuropathic pain. Expert Rev. Neurother., 2007, 7, 1597-612.
26. Swayne, L.A.; Bourinet, E. Voltage-gated calcium channels in chronic pain: emerging role of alternative splicing. Pflugers Arch., 2008, 456, 459-66.
27. Winquist, R.J.; Pan, J.Q.; Gribkoff, V.K. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem. Pharmacol., 2005, 70, 489-99.
28. Jevtovic-Todorovic, V.; Todorovic, S.M. Cell Calcium., 2006, 40, 197-203.
29. Haller, V.L.; Bernstein, M.A.; Welch, S.P. Chronic morphine treatment decreases the Cav1.3 subunit of the L-type calcium channel. Eur. J. Pharmacol., 2008, 578 101-7.
30. Gee, N.S.; Brown, J.P.; Dissanayake, V.U.; Offord, J.; Thurlow, R.; Woodruff, G.N. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J. Biol. Chem., 1996, 271, 5768-76.
31. Luo, Z.D.; Calcutt, N.A.; Higuera, E.S.; Valder, C.R.; Song, Y.H.; Svensson, C.Y.; Myers, R.R. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J. Pharmacol. Exp. Ther., 2002, 303, 1199-205.
32. Li, C.Y.; Zhang, X.L.; Matthews, E.A.; Li, K.W.; Kurwa, A.; Boroujerdi, A.; Gross, J.; Gold, M.S.; Dickenson, A.H.; Feng, G.; Luo, Z.D. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain, 2006, 125, 20-34.
33. Ohashi, K.; Kawai, M.; Ninomiya, N.; Taylor, C.; Kurebayashi, Y. Effect of a new alpha 2 delta ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats. Pharmacology, 2008, 81, 144-50.
34. Williams, J.A.; Day, M.; Heavner, J.E. Ziconotide: an update and review. Expert Opin. Pharmacother., 2008, 9, 1575-83.
35. Rasband, N.M.; Park, E.W.; Wanderah, T.W.; Lai, J.; Porreca, F.; Trimmer, J.S. Distinct potassium channels on pain-sensing neurons. Proc. Natl. Acad. Sci. USA, 2001, 98, 13373-8.
36. Hu, H.J.; Carrasquillo, Y.; Karim, F.; Jung, W.E.; Nerbonne, J.M.; Schwarz, T.L.; Gereau, R.W. The kv4.2 potassium channel subunit is required for pain plasticity. Neuron, 2006, 50, 89-100.
37. Huang, D.Y.; Yu, B.W.; Fan, Q.W. Roles of TRESK, a novel two-pore domain K+ channel, in pain pathway and general anesthesia. Neurosci. Bull., 2008, 24, 166-72.
38. Vit, J.P.; Ohara, P.T.; Bhargava, A.; Kelley, K.; Jasmin, L. Silencing the Kir4.1 potassium channel subunit in satellite glial cells of the rat trigeminal ganglion results in pain-like behavior in the absence of nerve injury. J. Neurosci., 2008, 28, 4161-71.
39. Munro, G.; Dalby-Brown, W. Kv7 (KCNQ) channel modulators and neuropathic pain. J. Med. Chem., 2007, 50, 2576-82.
40. Avendaño, C.; Machín, R.; Bermejo, P.E.; Lagares, A. Neuron numbers in the sensory trigeminal nuclei of the rat: a GABA- and glycine-immunocytochemical and stereological analysis. J. Comp. Neurol., 2005, 493, 538-53.
41. Pedersen, L.H.; Scheel-Krüger, J.; Blackburn-Munro, G. Amygdala GABA-A receptor involvement in mediating sensory-discriminative and affective-motivational pain responses in a rat model of peripheral nerve injury. Pain, 2007, 127, 17-26.
42. Choi, I.S.; Cho, J.H.; Jeong, S.G.; Hong, J.S.; Kim, S.J.; Kim, J.; Lee, M.G.; Choi, B.J.; Jang, I.S. GABA(B) receptor-mediated presynaptic inhibition of glycinergic transmission onto substantia gelatinosa neurons in the rat spinal cord. Pain, 2008, 138, 330-42.
43. Brown, S.M.; Dubin, A.E.; Chaplan, S.R. The role of pacemaker currents in neuropathic pain: the role of pacemaker currents in neuropathic pain. Pain Pract., 2004, 4, 182-93.
44. Parsons, C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol., 2001, 429, 71-8.
45. Boyce, S.; Wyatt, A.; Webb, J.K.; O'Donnell, R.; Mason, G.; Rigby, M. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology, 1999, 38, 611-23.
46. Bare, T.M.; Brown, D.G.; Horchler, C.L.; Murphy, M.; Urbanek, R.A.; Alford, V.; Barlaam, C.; Dyroff, M.C.; Empfield, J.B.; Forst, J.M.; Herzog, K.J.; Keith, R.A.; Kirschner, A.S.; Lee, C.M.; Lewis, J.; McLaren, F.M.; Neilson, K.L.; Steelman, G.B.; Trivedi, S.; Vacek, E.P.; Xiao, W. Pyridazinoquinolinetriones as NMDA glycine-site antagonists with oral antinociceptive activity in a model of neuropathic pain. J. Med. Chem., 2007, 50, 3113-31.
47. Mattia, C.; Coluzzi, F. Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs, 2007, 10, 636-44.
48. Parsons, C.G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol., 2001, 429, 71-8.
49. Hartmann, B.; Ahmadi, S.; Heppenstall, P.A.; Lewin, G.R.; Schott, C.; Borchardt, T.; Seeburg, P.H.; Zeilhofer, H.U.; Sprengel, R.; Kuner, R. The AMPA receptor subunits GluR-A and GluR-B reciprocally modulate spinal synaptic plasticity and inflammatory pain. Neuron, 2004, 44, 637-50.
50. Messeguer, A.; Planells-Cases, R.; Ferrer-Montiel, A. Physiology and pharmacology of the vanilloid receptor. Curr. Neuropharmacol., 2006, 4, 1-15.
51. Hudson, L.J.; Bevan, S.; Wotherspoon, G.; Gentry, C.; Fox, A.; Winter, J. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur. J. Neurosci., 2001, 13, 2105-14.
52. Fox, A.; Bevan, S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin. Investig. Drugs, 2005, 14, 695-703.
53. Staton, P.C.; Hatcher, J.P.; Walker, D.J.; Morrison, A.D.; Shapland, E.M.; Hughes, J.P.; Chong, E.; Mander, P.K.; Green, P.J.; Billinton, A.; Fulleylove, M.; Lancaster, H.C.; Smith, J.C.; Bailey, L.T.; Wise, A.; Brown, A.J.; Richardson, J.C.; Chessell, I.P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain, 2008, 139, 225-36.
54. Rowbotham, M.C.; Twilling, L.; Davies, P.S.; Reisner, L.; Taylor, K.; Mohr, D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N. Engl. J. Med., 2003, 348, 1223-32.
55. Gao, Y.; Xu, C.; Liang, S.; Zhang, A.; Mu, S.; Wang, Y.; Wan, F. Effect of tetramethylpyrazine on primary afferent transmission mediated by P2X3 receptor in neuropathic pain states. Brain Res. Bull., 2008, 77, 27-32.
56. Bettoni, I.; Comelli, F.; Rossini, C.; Granucci, F.; Giagnoni, G.; Peri, F.; Costa, B. Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia, 2008, 56, 1312-9.
57. Song, X.J.; Zheng, J.H.; Cao, J.L.; Liu, W.T.; Song, X.S.; Huang, Z.J. EphrinB-EphB receptor signaling contributes to neuropathic pain by regulating neural excitability and spinal synaptic plasticity in rats. Pain, 2008, 139, 168-80.
58. Okamoto, K.; Martin, D.P.; Schmelzer, J.D.; Mitsui, Y.; Low, P.A. Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp. Neurol., 2001, 169, 386-91.
59. Takahashi, N.; Nagano, M.; Suzuki, H.; Umino, M. Expression changes of glial cell line-derived neurotrophic factor in a rat model of neuropathic pain. J. Med. Dent. Sci., 2003, 50, 87-92.
60. Blom, S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet, 1962, 1, 839-40.
61. McQuay, H.; Carroll, D.; Jadad, A.R.; Wiffen, P.; Moore, A. Anticonvulsant drugs for management of pain: a systematic review. BMJ, 1995, 311, 1047-52.
62. Sommer, B.R.; Fenn, H.H.; Ketter, T.A. Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Expert Opin. Drug. Saf., 2007, 6, 133-45.
63. Bazil, C.W. Anticonvulsant drug or neuromodulator? The growing case for anticonvulsant uses beyond epilepsy. Curr. Neurol. Neurosci. Rep., 2004, 4, 350-7.
64. Mao, J.; Chen, L.L. Gabapentin in pain management. Anesth. Analg., 2000, 91, 680-7.
65. Taylor, C.P.; Gee, N.S.; Su, T.Z.; Kocsis, J.D.; Welty, D.F.; Brown, J.P.; Dooley, D.J.; Boden, P.; Singh, L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res., 1998, 29, 233-49.
66. Morello, C.M.; Leckband, S.G.; Stoner, C.P.; Moorhouse, D.F.; Sahagian, G.A. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med., 1999, 159, 1931-7.
67. Rowbotham, M.; Harden, N.; Stacey, B.; Bernstein, P.; Magnus-Miller, L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA, 1998, 280, 1837-42.
68. Pappagallo, M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin. Ther., 2003, 25, 2506-38.
69. Gajraj, N.M. Pregabalin: its pharmacology and use in pain management. Anesth. Analg., 2007, 105, 1805-15.
70. Freyhagen, R.; Strojek, K.; Griesing, T.; Whalen, E.; Balkenohl, M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain, 2005, 115, 254-63.
71. Taylor, C.P.; Vartanian, M.G.; Yuen, P.W.; Bigge, C.; Suman-Chauhan, N.; Hill, D.R. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin. Epilepsy Res., 1993, 14, 11-5.
72. Tölle, T.; Freynhagen, R.; Versavel, M.; Trostmann, U.; Young, J.P. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur. J. Pain, 2008, 12, 203-13.
73. Van Seventer, R.; Feister, H.A.; Young, J.P.; Stoker, M.; Versavel, M.; Rigaudy, L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr. Med. Res. Opin., 2006, 22, 375-84.
74. Vranken, J.H.; Dijkgraaf, M.G.; Kruis, M.R.; van der Vegt, M.H.; Hollmann, M.W.; Heesen, M. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain, 2008, 136, 150-7.
75. Tzellos, T.G.; Papazisis, G.; Amaniti, E.; Kouvelas, D. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. Eur. J. Clin. Pharmacol., 2008, 64, 851-8.
76. Arnold, L.M.; Russell, I.J.; Diri, E.W.; Duan, W.R.; Young, J.P.; Sharma, U.; Martin, S.A.; Barrett, J.A.; Haig, G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J. Pain, 2008, 9, 792-805.
77. Chong, M.S.; Libretto, S.E. The rationale and use of topiramate for treating neuropathic pain. Clin. J. Pain, 2003, 19, 59-68.
78. White, H.S.; Brown, D.; Skeen, G.A.; Twyman, R.E. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical netrons. Epilepsia, 1995, 36, 39.
79. Vinik, A.M.; Hewitt, D.; Xiang, J. Topiramate in the treatment of painful diabetic neuropathy: results from a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 2003, 60, A154-5.
80. Frampton, J.E.; Scott, L.J. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs, 2005, 19, 347-67.
81. Baulac, M.; Leppik, I.E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res., 2007, 75, 75-83.
82. Schauf, C.L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res., 1987, 413, 185-8.
83. Biton, V. Clinical pharmacology and mechanism of action of zonisamide. Clin. Neuropharmacol., 2007, 30, 230-40.
84. Hasegawa, H. Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr. Med. Res. Opin., 2004, 20, 577-80.
85. Patel, U.; Cheville, A.; Kim, P. A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. J. Pain, 2002, 3, 41.
86. Krusz, J.C. Treatment of chronic pain with zonisamide. Pain Pract., 2003, 3, 317-20.
87. Vestergaard, K.; Andersen, G.; Gottrup, H.; Kristensen, B.T.; Jensen, T.S. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology, 2001, 56, 184-90.
88. Rao, R.D.; Flynn, P.J.; Sloan, J.A.; Wong, G.Y.; Novotny, P.; Johnson, D.B.; Gross, H.M.; Renno, S.I.; Nashawaty, M.; Loprinzi, C.L. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer, 2008, 112, 2802-8.
89. White, H.S. Seizure frequency and duration of epilepsy are not risk factors for postoperative seizure outcome in patients with hippocampal sclerosis. Epilepsia, 1999, 40, 2-10.
90. Herranz, J.L.; Argumosa, A. Characteristics and indications of levetiracetam. Rev. Neurol., 2002, 35, 101-9.
91. Nasreddine, W.; Beydoun, A. Oxcarbazepine in neuropathic pain. Expert Opin. Investig. Drugs, 2007, 16, 1615-25.
92. Gillard, M.; Chatelain, P.; Fuks, B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur. J. Pharmacol., 2006, 536, 102-8.
93. Loscher, W.; Schmidt, D. New Horizons in the development of antiepileptic drugs: Innovative strategies. Epilepsy Res., 2006, 69, 183-272.
94. Enggaard, T.P.; Klitgaard, N.A.; Sindrup, S.H. Specific effect of levetiracetam in experimental human pain models. Eur. J. Pain, 2006, 10, 193-8.
95. Ardid, D.; Lamberty, Y.; Alloui, A.; Coudore-Civiale, M.A.; Klitgaard, H.; Eschalier, A. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur. J. Pharmacol., 2003, 473, 27-33.
96. Armijo, J.A.; Adín, J.; Sánchez, M.B. Mecanismo de acción de los antiepilépticos y nuevos antiepilépticos. Rev. Neurol., 2006, 43, 17-41.
97. Ben-Menachem, E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc.), 2008, 44, 35-40.
98. Beyreuther, B.; Callizot, N.; Stöhr, T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur. J. Pharmacol., 2006, 539, 64-70.
99. Porter, R.J.; Nohria, V.; Rundfeldt, C. Retigabine. Neurotherapeutics, 2007, 4, 149-54.
100. Wrinkler, I.; Blotnik, S.; Shimshoni, J.; Yagen, B.; Devor, M.; Bialer, M. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol., 2005, 146, 198-208.